Research map: Redefining First-Line HER2-Positive Advanced Gastric Cancer: From Trastuzumab-Based Chemoimmunotherapy to Zanidatamab and Next-Generation HER2 Targeting

Back to the article

Papers in this map

  1. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial · Yung‐Jue Bang · 2010 · 7408 citations · Cited by this paper
  2. Characteristics and Outcomes of Patients With Malignancies Prior to Colorectal Cancer: A Propensity Score Matched Analysis · 2026 · Related
  3. Comprehensive molecular characterization of gastric adenocarcinoma · Adam Joel Bass · 2014 · 6688 citations · Cited by this paper
  4. Treatment Outcomes and Prognostic Factors in Patients With Pancreatic Adenosquamous Carcinoma: a Single-Center Retrospective Study · 2026 · Related
  5. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer · Kohei Shitara · 2020 · 1352 citations · Cited by this paper
  6. Trends in Pancreatic Cancer Incidence, Mortality and Net Survival: A Population-Based Analysis in Zurich (Switzerland), 1981–2021 · 2026 · Related
  7. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial · Kohei Shitara · 2023 · 826 citations · Cited by this paper
  8. Factors Associated with Improved Survival for Stage I and II Pancreatic Adenocarcinoma Utilizing the National Cancer Database · 2026 · Related
  9. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer · Yelena Yuriy Janjigian · 2021 · 729 citations · Cited by this paper
  10. Access or Engagement: The Potential Role of Financial Incentives in Colorectal Cancer Screening · 2026 · Related
  11. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial · Sun Young Rha · 2023 · 698 citations · Cited by this paper
  12. Comment on “Efficacy of Radiotherapy Combined with Immunotherapy in MSS/pMMR Metastatic Colorectal Cancer: A Propensity-Matched Retrospective Study” · 2026 · Related
  13. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial · Manish A. Shah · 2023 · 657 citations · Cited by this paper
  14. Safety of Immune-Targeted Therapy in Patients with Hepatocellular Carcinoma in the Real-World · 2026 · Related
  15. Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2 -Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study · Taroh Satoh · 2014 · 630 citations · Cited by this paper
  16. Who Truly Benefits from Anti-EGFR Rechallenge in Metastatic Colorectal Cancer? From Clinical Enrichment to ctDNA-Guided Molecular Hyperselection · 2026 · Related
  17. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial · Joel Randolph Hecht · 2015 · 630 citations · Cited by this paper
  18. Gastric Cancer Incidence in Iran: Trends and Projections to 2030 based on Global Burden of Disease 2021 Estimates · 2026 · Related
  19. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer · Eric Van Cutsem · 2014 · 621 citations · Cited by this paper
  20. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study · Peter C Thuss-Patience · 2017 · 556 citations · Cited by this paper
  21. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial · Yelena Yuriy Janjigian · 2023 · 533 citations · Cited by this paper
  22. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study · Josep M. Tabernero · 2018 · 490 citations · Cited by this paper
  23. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study · Eric Van Cutsem · 2023 · 263 citations · Cited by this paper
  24. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology · Angela N. Bartley · 2016 · 255 citations · Cited by this paper
  25. HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma · Manish A. Shah · 2017 · 121 citations · Cited by this paper
  26. A Comprehensive and Comparative Review of Global Gastric Cancer Treatment Guidelines: 2024 Update · Sang Soo Eom · 2025 · 34 citations · Cited by this paper
  27. Trastuzumab deruxtecan in patients from China with previously treated human epidermal growth factor receptor 2–positive locally advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (DESTINY-Gastric06): results from a single-arm, multicenter, phase 2 trial · Zhi Peng · 2025 · 14 citations · Cited by this paper
  28. Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer · Kohei Shitara · 2026 · 13 citations · Cited by this paper
  29. Pembrolizumab with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer: health-related quality-of-life analysis from the randomized KEYNOTE-811 trial · Yelena Yuriy Janjigian · 2025 · 6 citations · Cited by this paper
  30. Phase Ib/II Study of Zanidatamab in Combination with Tislelizumab and Chemotherapy in First-Line HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma · Keun‐Wook Lee · 2025 · 5 citations · Cited by this paper
  31. Bispecific Antibodies and Antibody–Drug Conjugates in Advanced Gastric Adenocarcinoma · Jane Elizabeth Rogers · 2026 · 3 citations · Cited by this paper
  32. Clinicopathologic characteristics and genomic profiling of HER2-low advanced gastric or gastroesophageal junction cancer · C.K. Lee · 2026 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)